Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280678 | 0.77 | OPRM1 (0.44) | OPRL1OPRM1OPRK1CNR1CNR2 | |
| SCHEMBL14280676 | 0.77 | OPRM1 (0.52) | OPRL1OPRM1OPRK1CNR1CNR2 | |
| SCHEMBL4881230 | 0.75 | OPRL1 (0.67) | OPRL1OPRM1OPRK1OPRD1HRH2 | |
| SCHEMBL4881232 | 0.75 | OPRL1 (0.67) | OPRL1OPRM1OPRK1OPRD1HRH2 | |
| SCHEMBL14306729 | 0.75 | OPRL1 (0.66) | OPRL1OPRM1OPRK1OPRD1HRH2 | |
| SCHEMBL4882103 | 0.74 | HTR6 (0.50) | OPRL1OPRM1OPRK1CNR1CNR2 | |
| SCHEMBL14280679 | 0.73 | CNR1 (0.48) | OPRL1OPRM1OPRK1OPRD1CNR1 | |
| SCHEMBL14280691 | 0.73 | OPRL1 (0.81) | OPRL1OPRM1OPRK1OPRD1HRH2 | |
| SCHEMBL3899609 | 0.72 | HCRTR1 (0.52) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3901862 | 0.71 | OPRL1 (0.56) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRL1 2/4885OPRM1 11/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.